<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00614211</url>
  </required_header>
  <id_info>
    <org_study_id>LACC001</org_study_id>
    <nct_id>NCT00614211</nct_id>
  </id_info>
  <brief_title>Laparoscopic Approach to Cervical Cancer</brief_title>
  <acronym>LACC</acronym>
  <official_title>A Phase III Randomized Clinical Trial of Laparoscopic or Robotic Radical Hysterectomy Versus Abdominal Radical Hysterectomy in Patients With Early Stage Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queensland Centre for Gynaecological Cancer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queensland Centre for Gynaecological Cancer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to compare the long-term outcomes of different&#xD;
      surgical methods for the treatment of cervical cancer. The long-term outcome of a total&#xD;
      abdominal radical hysterectomy (TARH) will be compared against laparoscopy. In this study,&#xD;
      the laparoscopy will be done with or without robotic technology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To compare disease-free survival amongst patients who undergo a total laparoscopic (TLRH) or&#xD;
      robotic radical hysterectomy (TRRH) verses those who undergo a total abdominal radical&#xD;
      hysterectomy (TARH) for early stage cervical cancer.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  Compare patterns of recurrence between arms.&#xD;
&#xD;
        -  Compare treatment-associated morbidity within 6 months from surgery.&#xD;
&#xD;
        -  Compare the cost effectiveness of TLRH/TRRH versus TARH&#xD;
&#xD;
        -  Compare the impact on Quality of Life (QOL) between arms.&#xD;
&#xD;
        -  Assess pelvic floor function&#xD;
&#xD;
        -  Compare overall survival between arms&#xD;
&#xD;
        -  Determine the feasibility of sentinel lymph node biopsy in this group of patients&#xD;
&#xD;
      RATIONALE FOR STUDY DESIGN Total abdominal radical hysterectomy (TARH) and pelvic lymph node&#xD;
      dissection (± aortic lymph node dissection ± postoperative [chemo-] radiotherapy) is the&#xD;
      current standard treatment for early cervical cancer. While this is an accepted effective&#xD;
      treatment, a laparotomy is highly invasive, visibly scarring and is associated with tissue&#xD;
      trauma, blood loss and a significant risk of wound and infectious adverse events .&#xD;
      Additionally, radical hysterectomy by laparotomy is associated with an average hospital stay&#xD;
      of approximately 5 to 7 days and an average recovery period (from surgery) of 5 to 6 weeks.&#xD;
&#xD;
      Laparoscopic techniques have been demonstrated to be feasible and safe with previous&#xD;
      retrospective studies on TLH showing encouraging results . In a number of retrospective and&#xD;
      prospective, non-controlled series the incidence of treatment-related morbidity was less in&#xD;
      patients who had a laparoscopic hysterectomy compared to patients who underwent a TAH .&#xD;
      Retrospective data suggest that the recurrence rate and patterns of recurrence are similar in&#xD;
      patients who had a laparoscopic or an open approach .&#xD;
&#xD;
      Treatment recommendations ideally are based on prospective, randomized trials comparing the&#xD;
      current standard technique (TARH) with the proposed better technique (TLRH). However, there&#xD;
      are currently no prospective studies available which directly compare TLRH against the&#xD;
      standard treatment of TARH in regards to disease-free or overall survival.&#xD;
&#xD;
      The proposed clinical trial will be biphasic. The primary outcome variable in stage 1 will be&#xD;
      feasibility of recruitment as determined by overall trial recruitment. Following completion&#xD;
      of Stage 1, the data of this study will become the basis for assessing recurrence and&#xD;
      disease-free survival in the Stage 2 design.&#xD;
&#xD;
      RATIONALE FOR THE QUALITY OF LIFE Retrospective studies suggest equivalency between the&#xD;
      laparoscopic and open approaches to radical hysterectomy in regards to surgical specimens&#xD;
      obtained and likely disease-free and overall survivals . Thus, quality of life could be seen&#xD;
      as one of the most significant factors in recommending one approach over the other and&#xD;
      therefore an extremely important endpoint for this protocol. In the GOG LAP-2 protocol , a&#xD;
      trial evaluating a comparison between hysterectomy by laparotomy or laparoscopy, the&#xD;
      investigators found equivalency adequacy of the two surgical approaches however a significant&#xD;
      difference in short term quality of life favoring laparoscopy. As expected, patients who&#xD;
      underwent laparoscopy had a faster return to baseline functioning compared with those&#xD;
      patients who had undergone laparotomy which translated into improved short-term quality of&#xD;
      life. By 6 months, however, patients in both cohorts were reporting equivalent quality of&#xD;
      life parameters. Quality of life surveys employed with this Phase III clinical trial will&#xD;
      encompass important endpoints such as postoperative pain and related symptoms using the MD&#xD;
      Anderson Symptom Assessment Index (MDSAI), as well as cancer specific Functional Assessment&#xD;
      of Cancer Therapy (FACT-Cx) and the general 12-Item Short-Form Health Survey (SF-12).&#xD;
&#xD;
      RATIONALE FOR LYMPHATIC MAPPING Published experience with the techniques for lymphatic&#xD;
      mapping and sentinel lymph node detection in women with cervical cancer has been very&#xD;
      limited. To date, no single study has enrolled more than 100 patients undergoing lymphatic&#xD;
      mapping as part of their surgical treatment for cervical cancer. In fact, the majority of&#xD;
      studies report on less than 50 patients. In addition, this procedure has not yet been shown&#xD;
      to be viable in a multi-institutional setting. The limitations of previously published&#xD;
      reports are important as these techniques are associated with a significantly high learning&#xD;
      curve with early procedures less successful than later ones. This study will provide us the&#xD;
      opportunity to enroll large numbers of patients for validation of intraoperative lymphatic&#xD;
      mapping in women with cervical cancer in an international, multi-institutional setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years from surgery</time_frame>
    <description>Compare treatment equivalence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patterns of recurrence</measure>
    <time_frame>5 years from surgery</time_frame>
    <description>date and localization of 1st recurrence as confirmed histologically - Compare patterns between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs</measure>
    <time_frame>6 months from surgery</time_frame>
    <description>Compare costs between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life Questionnaires</measure>
    <time_frame>6 months from surgery</time_frame>
    <description>Compare QoL between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Distress Inventory Questionnaire</measure>
    <time_frame>5 years from surgery</time_frame>
    <description>Compare PFDI between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years from surgery</time_frame>
    <description>Compare between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of sentinel lymph node biopsy</measure>
    <time_frame>Intra-operatively</time_frame>
    <description>Compare between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-operative, peri-operative, post-operative and long term treatment related morbidity</measure>
    <time_frame>6 months from surgery</time_frame>
    <description>Compare these between groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">636</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Total Abdominal Radical Hysterectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total Laparoscopic or Robotic Radical Hysterectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Abdominal Radical Hysterectomy</intervention_name>
    <description>In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>TARH</other_name>
    <other_name>Open radical hysterectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Laparoscopic or Robotic Radical Hysterectomy</intervention_name>
    <description>In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>TLRH</other_name>
    <other_name>TRRH</other_name>
    <other_name>Keyhole radical hysterectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed primary adenocarcinoma, squamous cell carcinoma or&#xD;
             adenosquamous carcinoma of the uterine cervix;&#xD;
&#xD;
          -  Patients with Histologically confirmed stage IA1 (with lymph vascular invasion), stage&#xD;
             IA2, or stage IB1 disease&#xD;
&#xD;
          -  Patients undergoing either a Type II or III radical hysterectomy (Piver&#xD;
             Classification)&#xD;
&#xD;
          -  Patients with adequate bone marrow, renal and hepatic function:&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1.&#xD;
&#xD;
          -  Patient must be suitable candidates for surgery.&#xD;
&#xD;
          -  Patients who have signed an approved Informed Consent&#xD;
&#xD;
          -  Patients with a prior malignancy allowed if &gt; 5 years ago with no current evidence of&#xD;
             disease&#xD;
&#xD;
          -  Females, aged 18 years or older&#xD;
&#xD;
          -  Negative serum pregnancy test within &lt;30 days of surgery in pre-menopausal women and&#xD;
             women &lt; 2 years after the onset of menopause&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any histology other than adenocarcinoma, squamous cell carcinoma or adenosquamous&#xD;
             carcinoma of the uterine cervix;&#xD;
&#xD;
          -  Tumor size greater than 4 cm;&#xD;
&#xD;
          -  FIGO stage II-IV;&#xD;
&#xD;
          -  Patients with a history of pelvic or abdominal radiotherapy;&#xD;
&#xD;
          -  Patients who are pregnant;&#xD;
&#xD;
          -  Patients with contraindications to surgery;&#xD;
&#xD;
          -  Patients with evidence of metastatic disease by conventional imaging studies, enlarged&#xD;
             pelvic or aortic lymph nodes &gt; 2cm; or histologically positive lymph nodes&#xD;
&#xD;
          -  Unfit for Surgery: serious concomitant systemic disorders incompatible with the study&#xD;
             (at the discretion of the investigator);&#xD;
&#xD;
          -  Patients unable to withstand prolonged lithotomy and steep Trendelenburg position&#xD;
&#xD;
          -  Patient compliance and geographic proximity that do not allow adequate follow-up&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Ramirez, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Obermair, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Queensland Centre for Gynecological Cancer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Frumovitz, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Greater Baltimore Medical Centre</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Cancer Centre Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Luke's - Roosevelt Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peggy and Charles Stephenson Oklahoma Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77230-1439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Misericordia Hospital</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Wesley Hospital</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenslopes Private Hospital</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Health Services</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Townsville Hospital</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John of God</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erastus Gaertner Hospital</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Hospital</name>
      <address>
        <city>Morumbi</city>
        <state>San Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Brasileiro de Controlle do Cancer</name>
      <address>
        <city>Bras</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barretos Cancer Hospital</name>
      <address>
        <city>Barretos</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Pleven Center of Oncology Gynaecology</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affilated Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affliated Hospital of Wenzhou Medical College</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institito De Cancerologia Clinica Las Americas</name>
      <address>
        <city>Antioquia</city>
        <state>Medellin</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alessandro Manzoni Hospital</name>
      <address>
        <city>Lecco</city>
        <state>Milan</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Gerardo Hospital</name>
      <address>
        <city>Monza</city>
        <state>Milan</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of the Sacred Heart</name>
      <address>
        <city>Milan</city>
        <state>Rome</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Hospital</name>
      <address>
        <city>Goyang-si</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University - Department of Obstetrics and Gynecology</name>
      <address>
        <city>Ihwa-Dong</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASAN Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cencerologia</name>
      <address>
        <city>Tlalpan</city>
        <state>Mexico City</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Neoplasicas</name>
      <address>
        <city>Lima</city>
        <state>Surquillo</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gyneco-Oncologico Hospital HIMA</name>
      <address>
        <city>Caguas</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
    <country>India</country>
  </removed_countries>
  <link>
    <url>http://www.gyncan.org/</url>
    <description>QCGC Research</description>
  </link>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>Cancer Treatment and Research Centre</description>
  </link>
  <reference>
    <citation>Obermair A, Gebski V, Frumovitz M, Soliman PT, Schmeler KM, Levenback C, Ramirez PT. A phase III randomized clinical trial comparing laparoscopic or robotic radical hysterectomy with abdominal radical hysterectomy in patients with early stage cervical cancer. J Minim Invasive Gynecol. 2008 Sep-Oct;15(5):584-8. doi: 10.1016/j.jmig.2008.06.013.</citation>
    <PMID>18722970</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 31, 2008</study_first_submitted>
  <study_first_submitted_qc>February 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2008</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervix</keyword>
  <keyword>Cervical</keyword>
  <keyword>Cancer</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Radical hysterectomy</keyword>
  <keyword>Hysterectomy</keyword>
  <keyword>Laparoscopy</keyword>
  <keyword>Laparoscopic</keyword>
  <keyword>Robotic</keyword>
  <keyword>Squamous Cell</keyword>
  <keyword>Adenosquamous</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Lymphatic Mapping</keyword>
  <keyword>IOLM</keyword>
  <keyword>SPECT</keyword>
  <keyword>Sentinel Node</keyword>
  <keyword>Uterine cervix</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

